(Q51819134)

13 April 2018

review article

1 reference

title

Envisioning the future of early anticancer drug development. (English)

1 reference

13 April 2018

3

Paul Workman

1 reference

13 April 2018

Timothy A Yap

1

1 reference

13 April 2018

Shahneen K Sandhu

series ordinal

2

1 reference

13 April 2018

Johann S de Bono

series ordinal

4

1 reference

13 April 2018

language of work or name

English

0 references

publication date

10 June 2010

1 reference

13 April 2018

published in

Nature Reviews Cancer

1 reference

13 April 2018

volume

10

1 reference

13 April 2018

issue

7

1 reference

13 April 2018

page(s)

514-523

1 reference

13 April 2018

https://scigraph.springernature.com/pub.10.1038/nrc2870

exact match

0 references

1 reference

Cancer genes and the pathways they control

31 March 2020

1 reference

New approaches to molecular cancer therapeutics

31 March 2020

1 reference

Utilizing RNA interference to enhance cancer drug discovery

31 March 2020

1 reference

A perspective on challenges and issues in biomarker development and drug and biomarker codevelopment

31 March 2020

1 reference

Personalized cancer therapy with selective kinase inhibitors: an emerging paradigm in medical oncology

31 March 2020

1 reference

Factors underlying sensitivity of cancers to small-molecule kinase inhibitors

31 March 2020

1 reference

Targeted therapeutics for cancer treatment: major progress towards personalised molecular medicine

31 March 2020

1 reference

Economics of new oncology drug development

31 March 2020

1 reference

Development trends for new cancer therapeutics and vaccines.

31 March 2020

1 reference

Trends in risks associated with new drug development: success rates for investigational drugs

31 March 2020

1 reference

New science-based endpoints to accelerate oncology drug development

31 March 2020

1 reference

The use of genomics in clinical trial design

31 March 2020

1 reference

Pharmacodynamic biomarkers for molecular cancer therapeutics

31 March 2020

1 reference

What is the right dose? The elusive optimal biologic dose in phase I clinical trials

31 March 2020

1 reference

Pharmacogenetics and pharmacogenomics of anticancer agents.

31 March 2020

1 reference

Pharmacogenomic progress in individualized dosing of key drugs for cancer patients

31 March 2020

1 reference

Challenges of PK/PD measurements in modern drug development

31 March 2020

1 reference

How much gets there and what does it do?: The need for better pharmacokinetic and pharmacodynamic endpoints in contemporary drug discovery and development

31 March 2020

1 reference

Telomerase as a Target for Cancer Immunotherapy

31 March 2020

1 reference

Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies

31 March 2020

1 reference

Pharmacokinetic-pharmacodynamic relationships for the heat shock protein 90 molecular chaperone inhibitor 17-allylamino, 17-demethoxygeldanamycin in human ovarian cancer xenograft models

31 March 2020

1 reference

Antitumor activity with CYP17 blockade indicates that castration-resistant prostate cancer frequently remains hormone driven.

31 March 2020

1 reference

Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven.

31 March 2020

1 reference

Targeting CYP17: established and novel approaches in prostate cancer

31 March 2020

1 reference

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

31 March 2020

1 reference

Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers

31 March 2020

1 reference

Clinical trial designs for predictive biomarker validation: theoretical considerations and practical challenges.

31 March 2020

1 reference

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

31 March 2020

1 reference

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

31 March 2020

1 reference

Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study

31 March 2020

1 reference

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer

31 March 2020

1 reference

Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)

31 March 2020

1 reference

EGFR mutations predict survival benefit from gefitinib in patients with advanced lung adenocarcinoma: a historical comparison of patients treated before and after gefitinib approval in Japan

31 March 2020

1 reference

Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer

31 March 2020

1 reference

Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling

31 March 2020

1 reference

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

31 March 2020

1 reference

Randomized phase III clinical trial designs for targeted agents

31 March 2020

1 reference

Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promises

31 March 2020

1 reference

Drugging the PI3 kinome: from chemical tools to drugs in the clinic.

31 March 2020

1 reference

Drug development of MET inhibitors: targeting oncogene addiction and expedience

31 March 2020

1 reference

Targeting the HGF/c-Met axis: state of play.

31 March 2020

1 reference

Surrogate threshold effect: an alternative measure for meta-analytic surrogate endpoint validation

31 March 2020

1 reference

Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer

31 March 2020

1 reference

Evaluation of circulating tumor cells and serological cell death biomarkers in small cell lung cancer patients undergoing chemotherapy

31 March 2020

1 reference

Circulating tumour-derived predictive biomarkers in oncology

31 March 2020

1 reference

Ki67 in breast cancer: prognostic and predictive potential

31 March 2020

1 reference

Circulating tumor cells, disease progression, and survival in metastatic breast cancer

31 March 2020

1 reference

Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer

31 March 2020

1 reference

Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer.

31 March 2020

1 reference

Detection of mutations in EGFR in circulating lung-cancer cells

31 March 2020

1 reference

Maximizing mouse cancer models

31 March 2020

1 reference

Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941

31 March 2020

1 reference

Molecular pharmacology of phosphatidylinositol 3-kinase inhibition in human glioma

31 March 2020

1 reference

Biomarkers in early clinical trials: the committed and the skeptics

31 March 2020

1 reference

Biomarkers in phase I oncology trials: signal, noise, or expensive distraction?

31 March 2020

1 reference

Trends in the use and role of biomarkers in phase I oncology trials

31 March 2020

1 reference

The cancer biomarker problem

31 March 2020

1 reference

Rationale for biomarkers and surrogate end points in mechanism-driven oncology drug development

31 March 2020

1 reference

Phase I clinical trial design in cancer drug development

31 March 2020

1 reference

The multi-institutional phase I study: disadvantages without advantages?

31 March 2020

1 reference

Multi-institutional phase I trials of anticancer agents

31 March 2020

1 reference

High-throughput oncogene mutation profiling in human cancer

31 March 2020

1 reference

Beyond chemotherapy: targeted therapies in ovarian cancer

31 March 2020

1 reference

A comprehensive comparison of the continual reassessment method to the standard 3 + 3 dose escalation scheme in Phase I dose-finding studies

31 March 2020

1 reference

Continual reassessment method: a practical design for phase 1 clinical trials in cancer.

31 March 2020

1 reference

Dose selection in phase I studies: why we should always go for the top

31 March 2020

1 reference

Endpoints and other considerations in phase I studies of targeted anticancer therapy: recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies (MDICT)

31 March 2020

1 reference

Use of positron emission tomography in pharmacokinetic studies to investigate therapeutic advantage in a phase I study of 120-hour intravenous infusion XR5000.

31 March 2020

1 reference

Minimally invasive pharmacokinetic and pharmacodynamic technologies in hypothesis-testing clinical trials of innovative therapies

31 March 2020

1 reference

Phase I dose escalation study of the anti insulin-like growth factor-I receptor monoclonal antibody CP-751,871 in patients with refractory solid tumors

31 March 2020

1 reference

Maximum tolerated dose: clinical endpoint for a bygone era?

31 March 2020

1 reference

Optimising the design of phase II oncology trials: the importance of randomisation.

31 March 2020

1 reference

The design of phase II clinical trials testing cancer therapeutics: consensus recommendations from the clinical trial design task force of the national cancer institute investigational drug steering committee

31 March 2020

1 reference

Comparison of error rates in single-arm versus randomized phase II cancer clinical trials

31 March 2020

1 reference

Randomized phase II designs.

31 March 2020

1 reference

Cancer: drug-tolerant insurgents

31 March 2020

1 reference

Dynamic modularity in protein interaction networks predicts breast cancer outcome

31 March 2020

1 reference

A network view of disease and compound screening

31 March 2020

1 reference

The US Food and Drug Administration perspective on cancer biomarker development.

31 March 2020

1 reference

Use of pharmacokinetic/pharmacodynamic biomarkers to support rational cancer drug development

31 March 2020

1 reference

Gene expression profiling of human colon cancer cells following inhibition of signal transduction by 17-allylamino-17-demethoxygeldanamycin, an inhibitor of the hsp90 molecular chaperone.

31 March 2020

1 reference

Biomarker-driven early clinical trials in oncology: a paradigm shift in drug development

31 March 2020

1 reference

A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair

31 March 2020

1 reference

Project Zero Delay: a process for accelerating the activation of cancer clinical trials

31 March 2020

1 reference

Phase I trial design for solid tumor studies of targeted, non-cytotoxic agents: theory and practice

31 March 2020

1 reference

Drug development in oncology: classical cytotoxics and molecularly targeted agents

31 March 2020

1 reference

Dose escalation methods in phase I cancer clinical trials

31 March 2020

1 reference

Challenges and pitfalls of combining targeted agents in phase I studies

31 March 2020

1 reference

Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer

31 March 2020

1 reference

Auditing the pharmacological accounts for Hsp90 molecular chaperone inhibitors: unfolding the relationship between pharmacokinetics and pharmacodynamics.

31 March 2020

1 reference

12 December 2020

Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors

1 reference

12 December 2020

Inhibition of signal transduction by the Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin results in cytostasis and apoptosis.

1 reference

12 December 2020

Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval

1 reference

12 December 2020

Relevance of multidrug resistance in the age of targeted therapy

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRC2870

1 reference

13 April 2018

1 reference

13 April 2018